Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

被引:102
作者
Koch, S [1 ]
Hemrick-Luecke, SK [1 ]
Thompson, LK [1 ]
Evans, DC [1 ]
Threlkeld, PG [1 ]
Nelson, DL [1 ]
Perry, KW [1 ]
Bymaster, FP [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Lilly Neurosci Res Div, Indianapolis, IN 46285 USA
关键词
transporters; chlorimipramine; duloxetine; milnacipran; venlafaxine; serotonin; norepinephrine; depression;
D O I
10.1016/S0028-3908(03)00268-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Compounds that block both serotonin (5-HT) and norepinephrine (NE) transporters have been proposed to have improved antidepressant efficacy. We compared the ability of four dual transporter inhibitors-chlorimipramine, duloxetine, milnacipran and venlafaxine-to block monoamine transporters in vitro and in vivo and increase extracellular monoamines in rat brain. Inhibition of radioligand binding to clonal human monoamine transporters in vitro and in vivo in rats was determined. Extracellular concentrations of 5-HT and NE in rat prefrontal cortex (PFC) were quantified using the microdialysis technique. All compounds blocked binding to human 5-HT and NE transporters, although chlorimipramine and venlafaxine had markedly greater affinity for 5-HT than NE transporters. In vivo, chlorimipramine and duloxetine potently blocked both transporters, milnacipran blocked both with lower potency and venlafaxine only blocked the 5-HT transporter. Chlorimipramine and duloxetine increased robustly and approximately equally monoamine extracellular concentrations. Milnacipran produced only small increases in NE, whereas venlafaxine increased 5-HT markedly at the lower doses and both monoamines at high doses. Thus, the dual transporter inhibitors blocked 5-HT and NE transporters in vitro and in vivo with varying potency. Chlorimipramine, duloxetine, and high dose venlafaxine acted as dual transporter inhibitors in rat PFC and increased extracellular concentrations of the monoamines, indicating functional dual transporter inhibition. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:935 / 944
页数:10
相关论文
共 42 条
[1]  
Andersson B., 1987, Nuclear Physics A, VA461, p513c, DOI 10.1016/0375-9474(87)90510-0
[2]  
BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243
[3]  
Beasley C M Jr, 1993, Ann Clin Psychiatry, V5, P199, DOI 10.3109/10401239309148983
[4]   Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran - Microdialysis studies in rats [J].
Bel, N ;
Artigas, F .
NEUROPSYCHOPHARMACOLOGY, 1999, 21 (06) :745-754
[5]  
Burrows GD, 1998, J CLIN PSYCHIAT, V59, P4
[6]   Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder [J].
Bymaster, FP ;
Katner, JS ;
Nelson, DL ;
Hemrick-Luecke, SK ;
Threlkeld, PG ;
Heiligenstein, JH ;
Morin, SM ;
Gehlert, DR ;
Perry, KW .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (05) :699-711
[7]   Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors [J].
Bymaster, FP ;
Dreshfield-Ahmad, LJ ;
Threlkeld, PG ;
Shaw, JL ;
Thompson, L ;
Nelson, DL ;
Hemrick-Luecke, SK ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (06) :871-880
[8]   Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex [J].
Bymaster, FP ;
Zhang, W ;
Carter, PA ;
Shaw, J ;
Chernet, E ;
Phebus, L ;
Wong, DT ;
Perry, KW .
PSYCHOPHARMACOLOGY, 2002, 160 (04) :353-361
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine [J].
Clere, G .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (03) :145-151